2006
DOI: 10.1055/s-2005-870209
|View full text |Cite
|
Sign up to set email alerts
|

Collagen/Povidone as a New Endoscopic Treatment Option in Peptic Ulcer Bleeding

Abstract: We report here on a case of recurrent bleeding secondary to duodenal ulcer, de− spite previous endoscopic treatment with epinephrine and argon, which was con− trolled with endoscopic injection of col− lagen/povidone. This is a biological agent derived from gamma−irradiation of a mix− ture of type I pepsinated porcine collagen and povidone that has been reported to improve recovery during the healing pro− cess [1, 2].

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1
1
1

Citation Types

0
3
0

Year Published

2007
2007
2014
2014

Publication Types

Select...
2

Relationship

0
2

Authors

Journals

citations
Cited by 2 publications
(3 citation statements)
references
References 0 publications
0
3
0
Order By: Relevance
“…The amount of solution was chosen empirically and was injected only in and around the lesion and sprayed over the surface of the ulcer. This decision was supported by previous reports of cases in which collagen-PVP treatment was successfully used (injecting intramuscularly and subcutaneously for patients with rheumatoid arthritis and scleroderma, and application to the surface of dermatological ulcers secondary to venous insufficiency [4][5][6], as well as in the case described in our previous publication [3]). The patient consented to the use of the biological compound for treatment.…”
Section: Case Presentationmentioning
confidence: 58%
See 1 more Smart Citation
“…The amount of solution was chosen empirically and was injected only in and around the lesion and sprayed over the surface of the ulcer. This decision was supported by previous reports of cases in which collagen-PVP treatment was successfully used (injecting intramuscularly and subcutaneously for patients with rheumatoid arthritis and scleroderma, and application to the surface of dermatological ulcers secondary to venous insufficiency [4][5][6], as well as in the case described in our previous publication [3]). The patient consented to the use of the biological compound for treatment.…”
Section: Case Presentationmentioning
confidence: 58%
“…It also modulates collagen turnover by decreasing collagenolytic activity and tissue inhibitor of metalloproteinase-1 production and increasing the amount of type III collagen. This is possibly accomplished by downregulating proinflamamatory cytokines and adhesion molecules such as intercellular adhesion molecule-1, vascular cell adhesion molecule-1, interleukin-1beta, tumour necrosis factor-alpha and platelet-derived growth factor (3,(7)(8)(9)(10). Intralesional injection of collagen-PVP once a week for one to three months into human hypertrophic scars or scleroderma lesions diminishes pruritus, pain, erythema, volume and inflammatory infiltrates (5,11).…”
Section: Discussionmentioning
confidence: 99%
“…The physicochemical and pharmacological properties of this copolymer are derived from its components. C–PVP exhibits immunomodulatory and tissue-regenerative properties, which have been evidenced in different pathologies in acute and chronic stages in various fields, including orthopedics and trauma, vascular surgery, gynecology and gastroenterology, as well as dermatology and rheumatology. …”
Section: Introductionmentioning
confidence: 99%